Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000361
Status:
TERMINATED
Last Update Posted:
2006-04-24
First Post:
1999-11-02
Brief Title:
Autoimmunity in Inner Ear Disease
Sponsor:
National Institute on Deafness and Other Communication Disorders NIDCD
Organization:
National Institute on Deafness and Other Communication Disorders NIDCD
Study Overview
Official Title:
None
Status:
TERMINATED
Status Verified Date:
2006-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether prednisone methotrexate and cyclophosphamide are effective in the treatment of rapidly progressive sensorineural hearing loss in both ears This condition is called autoimmune inner ear disease AIED because it is thought that the hearing loss is triggered by an autoimmune process Treatment attempts to suppress or control this process with powerful anti-inflammatory drugs This is a Phase III outpatient study All study participants will be assigned to one of four different groups testing the experimental use of drugs The study is scheduled to run for 18 months with a minimum of 11 visits per participant
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U01DC003209 | NIH | None | httpsreporternihgovquickSearchU01DC003209 |